Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;72(5):e31606.
doi: 10.1002/pbc.31606. Epub 2025 Feb 14.

PET Response and Outcome in Low-Risk Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1

Lianna J Marks  1 , Yue Wu  2 , Kathleen M McCarten  3 , Lindsay A Renfro  4 , Qinglin Pei  2 , Kara M Kelly  5 , Cindy L Schwartz  6 , Sharon M Castellino  7 , Burton E Appel  8
Affiliations

PET Response and Outcome in Low-Risk Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1

Lianna J Marks et al. Pediatr Blood Cancer. 2025 May.

Abstract

A better understanding of positron emission tomography (PET) response in nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is critical for incorporating PET into prospective trials. PET scans from Children's Oncology Group study AHOD03P1 for patients less than 22 years with low-risk nLPHL, treated with three cycles of doxorubicin, vincristine, prednisone, and cyclophosphamide chemotherapy, were retrospectively reviewed and assigned Deauville 5-point scale (5PS) scores. Five-year post-PET event-free survival was 90.1% (80% CI: 85.2%-93.4%) for PET-negative (5PS 1-3) and 66.7% (80% CI: 36.4%-85.0%) for PET-positive (5PS 4-5) patients. PET response after three cycles of low-dose chemotherapy is predictive of relapse risk for low-risk nLPHL.

Keywords: nodular lymphocyte‐predominant Hodgkin lymphoma; pediatric; positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

References

    1. Park NJ, Hiniker SM, Guo HH, Advani RH, Hoppe RT, Binkley MS. Investigating PET Responses to Treatment in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Int J Radiat Oncol. 2023;117(2):E480–E.
    1. Marks LJ, Pei Q, Bush R, Buxton A, Appel B, Kelly KM, et al. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65(12):e27375. - PMC - PubMed
    1. Eichenauer DA, Kreissl S, Buhnen I, Baues C, Kobe C, van Heek L, et al. PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann Oncol. 2021;32(6):807–10. - PubMed
    1. Appel BE, Chen L, Buxton AB, Hutchison RE, Hodgson DC, Ehrlich PF, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2016;34(20):2372–9. - PMC - PubMed
    1. Untanu RV, Back J, Appel B, Pei Q, Chen L, Buxton A, et al. Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65(1). - PMC - PubMed

MeSH terms

LinkOut - more resources